RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.27
+1.64%Margins
Gross margin
-766.4%
EBITDA margin
—
EBIT margin
-6679.7%
Net margin
—
FCF margin
-5291.5%
122.9%
Return on equity
-48.3%
Return on assets
160.8%
Return on invested capital
0.00x
Asset turnover
-$76.1M
Cash from operations
$4.88
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026